|
|
Volumn 102, Issue 19, 2010, Pages 1456-1459
|
|
HPV-positive oropharyngeal cancer: data may justify new approach.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CANCER VACCINE;
CETUXIMAB;
CISPLATIN;
MONOCLONAL ANTIBODY;
ONCOPROTEIN;
ADJUVANT CHEMOTHERAPY;
ADJUVANT THERAPY;
ALPHAPAPILLOMAVIRUS;
DISEASE FREE SURVIVAL;
FOOD AND DRUG ADMINISTRATION;
GENE EXPRESSION REGULATION;
HUMAN;
IMMUNOLOGY;
ISOLATION AND PURIFICATION;
MORTALITY;
NOTE;
OROPHARYNX TUMOR;
PAPILLOMAVIRUS INFECTION;
PATHOGENICITY;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
SQUAMOUS CELL CARCINOMA;
SURVIVAL RATE;
UNITED STATES;
VIROLOGY;
VIRUS INFECTION;
ALPHAPAPILLOMAVIRUS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CANCER VACCINES;
CARCINOMA, SQUAMOUS CELL;
CHEMOTHERAPY, ADJUVANT;
CISPLATIN;
DISEASE-FREE SURVIVAL;
GENE EXPRESSION REGULATION, NEOPLASTIC;
HUMANS;
ONCOGENE PROTEINS, VIRAL;
OROPHARYNGEAL NEOPLASMS;
PAPILLOMAVIRUS INFECTIONS;
PROGNOSIS;
RADIOTHERAPY, ADJUVANT;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SURVIVAL RATE;
TUMOR VIRUS INFECTIONS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 77958150009
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djq403 Document Type: Note |
|
Times cited : (10)
|
|
References (0)
|
